<DOC>
	<DOCNO>NCT00329537</DOCNO>
	<brief_summary>The purpose study assess tolerability , pharmacokinetics safety 2 6 micro g/kg/day sargramostim administer subcutaneously daily 4 week , assess efficacy safety 6 micro g/kg/day sargramostim administer subcutaneously daily 8 week comparison placebo , patient moderately severely active Crohn 's disease .</brief_summary>
	<brief_title>Study Sargramostim Moderately Severely Active Crohn 's Disease</brief_title>
	<detailed_description>On 29 May 2009 , Bayer begin transition sponsorship trial Genzyme . NOTE : This study originally post sponsor Berlex , Inc. Berlex , Inc. rename Bayer HealthCare , Inc .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Confirmed diagnosis Crohn 's disease ( endoscopic radiological evaluation ) least 4 month prior receive first dose study drug Moderately severely active Crohn 's disease time screen ( i.e. , Crohn 's disease activity index [ CDAI ] &gt; 220 &lt; 475 point ) Colostomy ileostomy Immediate need gastrointestinal ( GI ) surgery active GI bleeding , peritonitis , intestinal obstruction , intraabdominal perianal abscess require surgical drainage GI surgery within 6 month prior receive 1st dose study drug Symptoms bowel obstruction confirm evidence clinicallysignificant stricture within last 6 month surgically correct</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>CDAI</keyword>
	<keyword>Moderately severely active Crohn 's Disease</keyword>
</DOC>